

Memphasys Welcomes Lindley Edwards as Chair as commercialisation milestones advance

Memphasys Limited (ASX: MEM) (“the Company”) is pleased to announce the appointment of Ms. Lindley Edwards as Non-Executive Chairperson, effective following the 2024 AGM and from 23 November 2024. She will replace Mr. Robert Cooke, who is stepping down as a Director of the Company at the AGM to focus on other executive commitments.

Ms. Edwards brings over 30 years of experience in financial services, corporate governance, and strategic advisory roles. Currently the CEO of AFG Venture Group, Ms. Edwards specialises in mergers, acquisitions, strategic partnerships, and technology commercialisation. She has a proven track record in corporate governance, risk management, and executing growth strategies across diverse industries.

Her academic qualifications include a Bachelor of Business (Accounting) from Monash University, a Bachelor of Business (Banking and Finance) from Victoria University, and a Postgraduate Diploma in Corporate Governance for ASX-listed Companies from Kaplan. She has also undertaken advanced studies in digitisation and innovation, earning a MicroMasters in Digitisation from Boston University and a PhD in Philosophy from Ubiquity University.

This leadership change occurs at a key time for Memphasys as the company approaches the completion of its pivotal clinical trial for the Felix™ System, with 95% of patient recruitment finalised¹. The trial is expected to conclude by the end of 2024. The Felix™ System is a proprietary sperm separation technology designed to improve outcomes in assisted reproductive treatments. Positive trial results will provide critical data for regulatory submissions and are expected to facilitate commercial discussions with distributors, strategic partners, and investors.

The company is also advancing its RoXsta™ System, which recently achieved provisional patent approval. This system, designed for rapid measurement of oxidative stress, has broad applications in human and animal health and supports Memphasys’ ongoing innovation strategy².

The Board acknowledges Mr. Cooke’s significant contributions, which have positioned Memphasys for its next phase of growth.

Commenting on her appointment, Ms. Edwards said:

“I am pleased to join Memphasys during this important stage of its development. The Felix™ System and RoXsta™ System present exciting opportunities for the company to expand its impact in the global fertility and biotechnology markets.”

The Board is confident that Ms. Edwards’ appointment will support Memphasys’ strategic objectives as the company advances its innovative technologies towards global commercialisation.

This announcement has been approved for release by the Board of Memphasys Limited.

ENDS

¹ Refer ASX announcement dated 18 November 2024

² Refer ASX announcement dated 15 November 2024

For further information, please contact:

Dr David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bio separation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.